<DOC>
	<DOCNO>NCT00640159</DOCNO>
	<brief_summary>Parkinson 's disease ( PD ) progressive neurodegenerative disease . Symptomatic therapy primarily aim restore dopamine function brain . Oral selegiline conjunction L-dopa mainstay therapy PD patient experience motor fluctuation many year . The mechanisms accounting selegiline 's beneficial adjunctive action treatment PD fully understood . Inhibition monoamine oxidase ( MAO ) type B ( MAO-B ) activity generally consider primary importance . Oral selegiline low bio-availability typically dose BID , total 5-10 mg daily . Recently , FDA approve new orally disintegration tablet ( ODT ) formulation selegiline , call ZelaparTM . This new formulation utilizes Zydis technology dissolve mouth , absorption oral mucosa , thereby largely bypass gut avoid first pas hepatic metabolism . This allow active drug deliver low dose . Consequently , Zelapar dose once-daily , 2.5 mg per day . There empirical data indicate whether use new approve formulation selegiline ODT ( Zelapar ) superior preferred patient compare traditional oral selegiline . It believe clinical efficacy preserve enhanced , deliver active drug , improve patient preference ODT formulation due once-daily dose . The effectiveness orally disintegrate selegiline adjunct carbidopa/levodopa treatment PD establish multicenter randomize placebo-controlled trial ( n=140 ; 94 receive orally disintegrate selegiline , 46 receive placebo ) three month ' duration . Patients randomize orally disintegrate selegiline receive daily dose 1.25 mg first 6 week daily dose 2.5 mg last 6 week . Patients treat levodopa could additionally dopamine agonist , anticholinergic , amantadine , combination trial . At 12 week , orally disintegrate selegiline-treated patient average 2.2 hour per day le `` OFF '' time compare baseline . Placebo treat patient 0.6 hour per day le `` OFF '' time compare baseline . These difference significant ( p &lt; 0.001 ) . Adverse event similar drug placebo .</brief_summary>
	<brief_title>Tolerability Efficacy Switch From Oral Selegiline Orally Disintegrating Selegiline ( Zelapar ) Patients With Parkinson 's Disease</brief_title>
	<detailed_description>This open label , multicenter , 6 week study conversion oral selegiline orally disintegrate selegiline PD patient without motor fluctuation , currently take levodopa . The study consist substitution oral selegiline 1.25 mg orally disintegrate selegiline 10 day , titration orally disintegrate selegiline 2.5 mg per day next 30 day . The study consist 2 study visit clinic : Baseline Day 40 , telephone visit Day 10 . Inclusion Criteria : 1 . Idiopathic PD confirm least two follow sign : rest tremor , bradykinesia , rigidity 2 . Male female outpatient 3 . Age 30-90 year 4 . Current use levodopa oral selegiline ( 5-10 mg /day ) , stable least 1 month well tolerate 5 . Positive treatment response current anti-parkinsonian medication opinion investigator 6 . Acceptable contraception female child bear potential 7 . Willing able comply study procedure . 8 . Willing able give write informed consent prior begin study procedure . Exclusion Criteria : 1 . Atypical parkinsonism due drug , metabolic disorder , encephalitis , trauma , neurodegenerative disease . 2 . Significant cognitive psychiatric impairment , opinion investigator , would interfere ability complete test require protocol . 3 . Participation another clinical drug trial within previous four week . 4 . Patients medication contraindicate Zelapar ( include meperidine/Demerol , tramadol , methadone , propoxyphene , dextromethorphan , selegiline product ) 5 . Patients know hypersensitivity formulation selegiline inactive ingredient Zelapar , previous exposure orally disintegrate selegiline 6 . History melanoma 7 . Unstable/uncontrolled medical problem 8 . History drug/alcohol abuse 9 . Patients currently take rasagiline The primary efficacy point number subject prefer Zydis selegiline vs. number prefer oral selegiline , preference . Descriptive statistic use present percentage person adverse event resolution . The secondary endpoint include change UPDRS , PDQ-8 , BDI , FSS , ESS , rating global improvement change dyskinesia Baseline Day 40 visit . Appropriate parametric ( t-tests ) non-parametric analysis ( Wilcoxon sign rank comparison ) conduct base scale analyze . An intent treat approach use subject receive least one dose study medication include analysis .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Selegiline</mesh_term>
	<criteria>1 . Idiopathic PD confirm least two follow sign : rest tremor , bradykinesia , rigidity 2 . Male female outpatient 3 . Age 3090 year 4 . Current use levodopa oral selegiline ( 510 mg /day ) , stable least 1 month well tolerate 5 . Positive treatment response current antiparkinsonian medication opinion investigator 6 . Acceptable contraception female child bear potential 7 . Willing able comply study procedure . 8 . Willing able give write informed consent prior begin study procedure . 1 . Atypical parkinsonism due drug , metabolic disorder , encephalitis , trauma , neurodegenerative disease . 2 . Significant cognitive psychiatric impairment , opinion investigator , would interfere ability complete test require protocol . 3 . Participation another clinical drug trial within previous four week . 4 . Patients medication contraindicate Zelapar ( include meperidine/Demerol , tramadol , methadone , propoxyphene , dextromethorphan , selegiline product ) 5 . Patients know hypersensitivity formulation selegiline inactive ingredient Zelapar , previous exposure orally disintegrate selegiline 6 . History melanoma 7 . Unstable/uncontrolled medical problem 8 . History drug/alcohol abuse 9 . Patients currently take rasagiline</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>selegiline Zelapar switch</keyword>
	<keyword>orally disintegrate formulation</keyword>
</DOC>